Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, Pennsylvania, USA.
Pfizer AS, Lysaker, Norway.
APMIS. 2024 Nov;132(11):832-842. doi: 10.1111/apm.13475. Epub 2024 Oct 8.
Lyme borreliosis (LB), the most common tick-borne disease in Europe, is endemic to southern coastal Norway. LB commonly presents as erythema migrans, which can disseminate, resulting in more severe disease such as Lyme neuroborreliosis or arthritis. In Norway, public health LB surveillance is conducted via mandatory reporting of laboratory-confirmed disseminated cases. From 2012 to 2022, Norway's surveillance-reported incidence of laboratory-confirmed disseminated LB increased by 78%. Although surveillance provides estimates of the incidence of disseminated LB, this study sought to estimate the incidence of symptomatic LB to better understand Norway's LB disease burden. Two studies were identified that, when combined, estimated an LB seroprevalence of 6.8% in the general adult population in southern Norway. Utilizing data from these seroprevalence studies, public health surveillance, and results from literature searches indicating that 37% of seroconverted LB cases are symptomatic and that the duration of LB antibody detection ranges from 10 to 20 years, we estimated that there were 315-630 symptomatic LB cases per 100,000 adult population in five southern coastal counties in Norway in 2022 and 24-48 cases of symptomatic LB for every public health surveillance-reported LB case in adults in these five counties in Norway.
莱姆病（LB）是欧洲最常见的蜱传疾病，在挪威南部沿海地区流行。LB 通常表现为游走性红斑，可扩散，导致更严重的疾病，如莱姆神经Borreliosis 或关节炎。在挪威，通过对实验室确诊的散发病例进行强制性报告来进行公共卫生 LB 监测。2012 年至 2022 年，挪威监测报告的实验室确诊散发 LB 发病率增加了 78%。虽然监测提供了散发 LB 发病率的估计，但本研究旨在估计有症状 LB 的发病率，以更好地了解挪威的 LB 疾病负担。确定了两项研究，将这两项研究结合起来，可以估计挪威南部普通成年人群中 LB 血清流行率为 6.8%。利用这些血清流行率研究、公共卫生监测的数据，以及文献检索结果表明，37%的血清转化 LB 病例有症状，LB 抗体检测持续时间为 10 至 20 年，我们估计在 2022 年，挪威五个南部沿海县每 10 万成年人口中有 315-630 例有症状 LB 病例，在这些县的每 100 例成年人中，每例公共卫生监测报告的 LB 病例中有 24-48 例有症状 LB 病例。
